Sigma® Life Science launches suite of knockout rats to model Parkinson’s disease
Publication date: 17 March 2011
Author: kdm communications limited
Tagged with: Edward Weinstein, Sigma Life Science, Sigma-Aldrich
Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq:SIAL), have announced that its SAGE Labs initiative has created a suite of knockout rat models of Parkinson’s disease in collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Developed using the proprietary SAGEspeed™ model creation process, these off-the-shelf rat models represent a breakthrough in Parkinson’s disease research, overcoming the inherent limitations of the existing mouse models. For more information, on these animal models visit http://www.sageresearchmodels.com
Knockout rat models offer significant advantages over the existing mouse models, which do not effectively mimic the symptoms of Parkinson’s disease in humans. The neuronal circuitry of the rat model more closely imitates that of humans, better demonstrating the disease symptoms, and rats’ size and behavior allow researchers to perform a variety of experimental procedures more easily than in mice. In collaboration with MJFF, SAGE Labs has used Sigma Life Science’s CompoZr® Zinc Finger Nuclease (ZFN) technology to create a range of knockout rat models specific to Parkinson’s disease, based on existing knowledge of the key genes implicated in the disease. This groundbreaking collection of rat models currently includes LRRK2, Parkin, Pink1 and DJ-1 knockouts which will help researchers accelerate investigation of novel therapeutic strategies for Parkinson’s disease.
“This collaboration with The Michael J. Fox Foundation for Parkinson’s Research highlights the enormous potential of our CompoZr and SAGEspeed technology platforms, and displays our commitment to providing the scientific community with tools for cutting-edge research into diseases that afflict the human population,” said Dr. Edward Weinstein, Director of SAGE Labs at Sigma Life Science.
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Fast plasma sample cleanup with new Phree Phospholipid Removal Plates (21 May 2012)
- Two overall winners announced at prestigious national award ceremony in London’s Science Museum (18 May 2012)
- New analysis of risk stratification for TYSABRI® published in New England Journal of Medicine (18 May 2012)
- NUCYNTA® ER (tapentadol) tablets provide pain management for patients with Diabetic Peripheral Neuropathy (DPN) (18 May 2012)
- GSK statement on tender offer to acquire Human Genome Sciences (18 May 2012)
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content